ClinicalTrials.gg
RecruitingNCT06841575Updated Mar 25, 2026

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

An interventional study of Auto-aligned OCT in Eye Diseases, Retinal Disease and Glaucoma, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 1 Month and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Duke University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
1 Month and older
Sex
All
01

Study summary

The goal of the current study is to conduct a pilot study to test a new version of the handheld OCT device capable of auto-alignment to image the retina in adult volunteers, and adult and pediatric patients in clinic.

Read the detailed description

Handheld OCT imaging is an advancement in ophthalmic imaging technology allowing us to image the pediatric retina. lt has tremendous potential to be applied to assess the structure and blood flow of children with retinal vascular diseases or as a screening tool for pediatric retinal diseases. Despite progress in the development of hand-held OCT probes, there remains a critical gap in technology to achieve fast, proper alignment between the imaging device and the infant eye. Even with the most skilled operators, to acquire consistent OCT and OCTA data capture for longitudinal follow up in uncooperative patients at the bedside remains difficult. lmprovements in hand-held OCT probe technology for auto-alignment to the patient's eye, as well as on-line detection of image quality and auto-saving at the proper time, would address this critical gap in handheld OCT technology. Our biomedical engineering team, has developed prior iterations of the handheld OCT devices and successfully imaged the pediatric retina. The goal of the current study is to conduct a pilot study to test a new version of the handheld OCT device capable of auto-alignment to image the retina in adult volunteers, and adult and pediatric patients in clinic.

The investigators plan to enroll 20 healthy adult volunteers, 20 adult patients and 10 pediatric patients from the ophthalmology clinic. This is an observational study. There are no known risks associated with handheld OCT imaging and no adverse events identified imaging with prior iterations of handheld OCT devices. lmaging data will be downloaded to a secure server for protocol image processing, segmentation, and analysis per protocol in the Duke Advanced Research in SS/SDOCT lmaging (DARSI) laboratory.

02

Conditions studied

  • Eye Diseases
  • Retinal Disease
  • Glaucoma
  • Optic Nerve Diseases

Keywords

  • Optical Coherence Tomography (OCT)
03

In context

Eye Diseases

389 studies on the registry are indexed under Eye Diseases; 62 are open to participants now.

This study's planned enrollment of 50 is below the median of 62 across 269 interventional studies indexed under Eye Diseases.

Browse Eye Diseases studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group 1: Healthy adult volunteers
  • Subject is able and willing to consent to study participation
  • Subject is more than 18 years of age
  • Healthy adult volunteers without known ocular issues other than refractive error
  • Group 2: Adult patients in ophthalmology clinics
  • Health care provider, knowledgeable of protocol, agrees that study personnel could contact the subject
  • Subject is able and willing to consent to study participation
  • Subject is more than 18 years of age and is a patient in the Duke Eye Center ophthalmology clinics
  • Group 3: Pediatric participants in ophthalmology clinics
  • Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent/legal guardian
  • Parent/legal guardian is able and willing to consent to study participation
  • Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center

Exclusion criteria

Exclusion Criteria:

  • Group 1: Healthy adult volunteers
  • Students or employees under direct supervision of the investigators
  • Subjects with prior problems with pupil dilation
  • Pregnant woman if receiving dilating drops
  • Group 2: Adult patients in ophthalmology clinics
  • Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)
  • Group 3: Pediatric participants in ophthalmology clinics
  • Parent/legal guardian unwilling or unable to provide consent
  • Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Group 1: Healthy adult volunteers

    Healthy adult volunteers recruited from the patient population, students or employees of Duke University or Duke Eye Center (n=20)

    Device: Auto-aligned OCT

  • Experimental
    Group 2: Adult patients in ophthalmology clinics

    Adult participants recruited from the patient population of Duke Eye Center undergoing clinical examination (n=20)

    Device: Auto-aligned OCT

  • Experimental
    Group 3: Pediatric patients in ophthalmology clinics

    Minor participants recruited from the patient population of Duke Eye Center undergoing clinical examination (n=10)

    Device: Auto-aligned OCT

Interventions

  • DeviceAuto-aligned OCT

    Swept Source OCT system with improved hand-held probe technology for auto-alignment to the patient's eye, as well as on-line detection of image quality and auto-saving at the proper time

06

What researchers measure

Primary outcomes

  1. Number of participants with abnormal retinal microanatomy

    Measured by optical coherence tomography (OCT) reading.

    Time frame: Up to 4 single imaging sessions at clinical visits over 2 years

  2. Severity of abnormal retinal microanatomy

    Measured by optical coherence tomography (OCT) reading.

    Time frame: Up to 4 single imaging sessions at clinical visits over 2 years

  3. Retinal thickness (microns) at the fovea and surrounding optic nerve as measured by OCT analysis

    Measured by optical coherence tomography (OCT) analysis.

    Time frame: Up to 4 single imaging sessions at clinical visits over 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 49 non-industry interventional studies with no phase under Eye Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 68 studies reached it within 24 months; a quarter within 9 and three quarters within 49.

Eye Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 24, 2025
StartActual
Mar 23, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841575
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 23, 2026
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 25, 2026

Study contacts

Xi Chen, MD, PhD
Contact
xi2.chen@duke.edu
(919) 684-8434
Michelle N McCall, MCAPM, BA
Contact
michelle.mccall@duke.edu
(919) 684-0544
Xi Chen, MD, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion